Literature DB >> 2582442

Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors.

M M O'Hare1, T W Schwartz.   

Abstract

The expression of the potent vasoactive peptide neuropeptide Y (NPY) was studied in 16 clinically and/or histologically diagnosed human pheochromocytomas and 3 human neuroblastoma tumors. All tumors contained NPY in concentrations ranging from 21 pmol/g of tissue, similar to that found in normal adrenal tissue, to 91,000 pmol/g (median, 1,700 pmol/g). Three control tumors of Cushing's type did not contain NPY. An almost total proteolytic processing of pro-NPY to normal NPY was observed in the tumors (median, 93%; range, 72-100%). A positive correlation between the processing efficiency and the NPY content was also observed. The small amount of pro-NPY found in the tumors was characterized by "in vitro conversion" with endoproteinase Lys-C. In the tumor extracts, the majority of the NPY immunoreactivity, corresponding in size to the NPY standard, also behaved like synthetic NPY by high performance liquid chromatography and isoelectric focusing. As assessed by both its elution position in isoelectric focusing and its reaction with an antiserum specific for the COOH-terminal amidated sequence, the peptide produced by the tumors was found to be efficiently amidated, a modification which is essential for the biological activity of NPY. It is concluded that although only a subset of chromaffin cells express NPY, a very high number of pheochromocytomas and neuroblastomas produce correctly amidated and thus biologically active NPY in large amounts, and that this is of potential importance for tumor-related cardiovascular symptoms and for autocrine stimulation of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582442

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma.

Authors:  Erwan Thouennon; Alice Pierre; Laurent Yon; Youssef Anouar
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

2.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

3.  Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

Authors:  P deS Senanayake; J Denker; E L Bravo; R M Graham
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  Differential processing of neuropeptide proprotein in human breast adenocarcinoma.

Authors:  J H Zhang; D Zhou; J You; B S Tang; P Y Li; S S Tang
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

5.  Distribution of peptidyl-glycine alpha-amidating monooxygenase immunoreactivity in the brain, pituitary and islet organ of the anglerfish (Lophius americanus).

Authors:  J K McDonald; K Klein; B D Noe
Journal:  Cell Tissue Res       Date:  1995-04       Impact factor: 5.249

6.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

7.  Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours.

Authors:  P Bjellerup; E Theodorsson; H Jörnvall; P Kogner
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.